Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on Eupraxia Pharmaceuticals. The associated price target remains the same with $12.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight the potential of Eupraxia Pharmaceuticals’ EP-104GI as a best-in-class treatment for eosinophilic esophagitis (EoE). The company’s innovative use of its DiffuSphere polymer-based microsphere technology aims to provide a long-acting fluticasone propionate injectable suspension, which could offer significant advantages over current therapies. This includes the potential for once-annual dosing during routine endoscopy, addressing the limitations of existing treatments such as short-term oral steroids and frequently injected biologics.
Furthermore, the ongoing clinical trials, including the Phase 2b portion of the RESOLVE trial, are expected to provide crucial data that could drive value inflection points for the stock. With a growing EoE market in the U.S. and a current market cap that does not fully reflect the clinical data generated, Eupraxia is well-positioned to capture market share. The company’s financial position, with sufficient cash to fund operations into Q3 2026, also supports the Buy rating as it progresses towards Phase 3 readiness.
Folkes covers the Healthcare sector, focusing on stocks such as Omeros, Eupraxia Pharmaceuticals, and Trevi Therapeutics. According to TipRanks, Folkes has an average return of -6.4% and a 33.46% success rate on recommended stocks.
In another report released on July 30, Raymond James also reiterated a Buy rating on the stock with a $12.00 price target.